Free Trial

Alaunos Therapeutics Q2 2024 Earnings Report

Alaunos Therapeutics logo
$2.95 -1.27 (-30.09%)
As of 04/4/2025 04:00 PM Eastern

Alaunos Therapeutics EPS Results

Actual EPS
-$0.71
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Alaunos Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alaunos Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Alaunos Therapeutics Earnings Headlines

Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
See More Alaunos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alaunos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alaunos Therapeutics and other key companies, straight to your email.

About Alaunos Therapeutics

Alaunos Therapeutics (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

View Alaunos Therapeutics Profile

More Earnings Resources from MarketBeat